Prognostic effect of human leukocyte antigen class I and II alleles on chronic hepatitis C patients treated by pegylated interferon-alfa plus ribavirin in Taiwan

Hepato-Gastroenterology

Volumn 57, Issue 99-100, 2010, Pages 456-461

  Tseng, Kuo Chih ^a,b,c   Chang, Chin Kuo ^d   Chou, An Liang ^a   Hsieh, Yu Hsi ^a,b   Tseng, Chang An ^a,b   Lai, Ning Sheng ^a,b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Hepatitis C; Human leukocyte antigen; Interferon; Prognosis

Indexed keywords

ALANINE AMINOTRANSFERASE; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA B60 ANTIGEN; HLA C ANTIGEN; HLA CW ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; FEMALE; GENE LOCUS; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TAIWAN; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ALLELES; DRUG THERAPY, COMBINATION; FEMALE; GENES, MHC CLASS I; GENES, MHC CLASS II; HEPATITIS C, CHRONIC; HLA-DR ANTIGENS; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS; RIBAVIRIN; RNA, VIRAL;

EID: 77955479835     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19:1-46.
2. Fried MW, Shiffman ML, Reddy KR, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
3. Manns MP, McHutchison JG, Gordon SC, et al: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
4. Tsubota A, Chayama K, Ikeda K, et al: Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19:1088-1094.
5. Shiratori Y, Kato N, Yokosuka O, et al: Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997; 113:558-566. (Pubitemid 27351783)
6. Fried MW, Shiffman M, Sterling RK, et al: A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype. Am J Gastroenterol 2000; 95:3225-3229.
7. Ebeling F, Lappalainen M, Vuoristo M, et al: Factors predicting interferon treatment response in patients with chronic hepatitis c: late viral clearance does not preclude a sustained response. Am J Gastroenterol 2001; 96:1237-1242.
8. Izopet J, Payen JL, Alric L, et al: Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy. J Med Virol 1998; 54:86-91.
9. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
10. Parham P, Adams EJ, Arnett KL: The origins of HLA-A,B,C polymorphism. Immunol Rev 1995; 143:141-180.
11. Racioppi L, Ronchese F, Schwartz RH, Germain RN: The molecular basis of class II MHC allelic control of T cell responses. J Immunol 1991; 147:3718-3727.
12. Congia M, Clemente MG, Dessi C, et al: HLA class II genes in chronic hepatitis C virus-infection and associated immunological disorders. Hepatology 1996; 24:1338-1341.
13. Alric L, Fort M, Izopet J, et al: Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997; 113:1675-1681.
14. Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R, Donaldson PT: Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol 1998; 29:207-213.
15. Minton EJ, Smillie D, Neal KR, Irving WL, Underwood JC, James V: Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. J Infect Dis 1998; 178:39-44.
16. Mangia A, Gentile R, Cascavilla I, et al: HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol 1999; 30:984-989.
17. Lechmann M, Schneider EM, Giers G, et al: Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. Eur J Clin Invest 1999; 29:337-343.
18. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC: Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999; 354:2119-2124.
19. Fanning LJ, Levis J, Kenny-Walsh E, Wynne F, Whelton M, Shanahan F: Viral clearance in hepatitis C (1b) infection: relationship with human leukocyte antigen class II in a homogeneous population. Hepatology 2000; 31:1334-1337.
20. Barrett S, Ryan E, Crowe J: Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J Hepatol 1999; 30:979-983.
21. Muto H, Tanaka E, Matsumoto A, Yoshizawa K, Kiyosawa K: Nagano Interferon Treatment Research Group. Types of human leukocyte antigen and decrease in HCV core antigen in serum for predicting efficacy of interferon-Alpha in patients with chronic hepatitis C: analysis by a prospective study. J Gastroenterol 2004; 39:674-680.
22. Miyaguchi S, Saito H, Ebinuma H, Morizane T, Ishii H: Possible association between HLA antigens and the response to interferon in Japanese patients with chronic hepatitis C. Tissue Antigens 1997; 49:605-611.
23. Wang LY, Lin HH, Lee TD, et al: Human leukocyte antigen phenotypes and hepatitis C viral load. J Clin Virol 2005; 32:144-150.
24. Almarri A, El Dwick N, Al Kabi S, et al: Interferon-alpha therapy in HCV hepatitis: HLA phenotype and cirrhosis are independent predictors of clinical outcome. Hum Immunol 1998; 59:239-242.
25. Kikuchi I, Ueda A, Mihara K, et al: The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1998; 10:859-863.
26. Sim H, Wojcik J, Margulies M, Wade JA, Heathcote J: Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C. J Viral Hepat 1998; 5:249-253.
27. Alric L, Izopet J, Fort M, et al: Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection. Hum Immunol 1999; 60:516-523.
28. Yu ML, Dai CY, Chen SC, et al: Human leukocyte antigen class I and II alleles and response to interferon-alpha treatment, in Taiwanese patients with chronic hepatitis C virus infection. J Infect Dis 2003; 188:62-65.
29. Romero-Gómez M, González-Escribano MF, Torres B, et al: HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. Am J Gastroenterol 2003; 98:1621-1626.
30. Rhodes SL, Erlich H, Im KA, et al: Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection. Genes Immun 2008; 9:328-333.
31. Ratge D, Scheiblhuber B, Nitsche M, Knabbe C: High-speed detection of blood-borne hepatitis C virus RNA by single-tube real-time fluorescence reverse transcription-PCR with the LightCycler. Clin Chem 2000; 46:1987-1989.
32. Bullock GC, Bruns DE, Haverstick DM: Hepatitis C genotype determination by melting curve analysis with a single set of fluorescence resonance energy transfer probes. Clin Chem 2002; 48:2147-2154.
33. Hwang SH, Sohn YH, Oh HB, et al: Human leukocyte antigen alleles and haplotypes associated with chronicity of hepatitis B virus infection in Koreans. Arch Pathol Lab Med 2007; 131:117-121.
34. Chang LY, Chang IS, Chen WJ, et al: HLA-A33 is associated with susceptibility to enterovirus 71 infection. Pediatrics 2008; 122:1271-1276.
35. Hossain MS, Tomiyama H, Inagawa T, Ida S, Oka S, Takiguchi M: Identification and characterization of HLA-A*3303-restricted, HIV type 1 Pol- and Gag-derived cytotoxic T cell epitopes. AIDS Res. Hum Retroviruses 2003; 19:503-510.
36. Thursz M: MHC and the viral hepatitides. QJM 2001; 94:287-291.
37. Tilg H: New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997; 112:1017-1021.
38. Matsueda S, Yamada A, Takao Y, et al: A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31, and -A33. Cancer Immunol Immunother 2007; 56:1359-1366.
39. Lee SD, Yu ML, Cheng PN, et al: Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005; 12:283-291.
40. Yu ML, Dai CY, Lee LP, et al: A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. Liver Int 2006; 26:1187-1195.